Physician profile
Jared D Marks
NPI 1366453177
$6,383.59
in general payments reported to CMS, 2019-2025
29 companies · $1,093 in 2025
The $1,093 reported for 2025 was more than what 84% of Physician Assistant providers received nationally (typical 2025 total: $183).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2021: $815 · 2022: $1,287 · 2023: $1,680 · 2024: $1,509 · 2025: $1,093.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $4,214 · Education: $67.67.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $4,213.87 |
| Education | $67.67 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Genzyme Corporation | $1,889.09 | 2021-2025 | |
| Regeneron Healthcare Solutions, INC. | $777.32 | 2021-2025 | Dupixent |
| Astrazeneca Pharmaceuticals Lp | $657.11 | 2021-2025 | Fasenra, Airsupra, Tezspire |
| Glaxosmithkline, LLC. | $631.97 | 2021-2025 | Nucala, Trelegy Ellipta, Arexvy |
| Inspire Medical Systems, INC. | $336.30 | 2024-2025 | Inspire |
| Kaleo, INC. | $313.88 | 2021-2024 | Auvi-Q |
| Amgen INC. | $290.51 | 2021-2025 | Tezspire |
| Alk-Abello, INC | $181.71 | 2021-2023 | Odactra, Grastek, Ragwitek |
| Intersect Ent, INC. | $149.07 | 2021 | |
| Novartis Pharmaceuticals Corporation | $140.50 | 2021-2024 | |
| Genentech USA, INC. | $134.07 | 2022-2024 | Xolair |
| Takeda Pharmaceuticals U.S.A., INC. | $110.56 | 2021-2024 | Cuvitru, Takhzyro |
| Integra Lifesciences Corporation | $101.84 | 2025 | Relieva Spinplus Nav, Trudi Probe, Inspira Air |
| Csl Behring | $91.62 | 2021-2024 | Hizentra |
| Boehringer Ingelheim Pharmaceuticals, INC. | $90.97 | 2021-2022 |
Show all 29 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Pfizer INC. | $76.77 | 2021-2023 | |
| Leo Pharma INC. | $75.69 | 2022 | |
| Abbvie INC. | $68.92 | 2022-2023 | |
| Hikma Pharmaceuticals USA | $41.86 | 2022-2023 | Ryaltris |
| Acclarent, INC | $40.25 | 2023 | Trudi Nav Cable |
| Organon LLC | $33.39 | 2025 | Vtama |
| Spirair, INC. | $23.55 | 2024 | Septalign |
| Ars Pharmaceuticals Operations, INC. | $21.47 | 2025 | Neffy |
| Phadia US INC. | $21.31 | 2024 | Immunocap |
| Grifols USA, LLC | $19.09 | 2024 | Xembify |
| Teva Pharmaceuticals USA, INC. | $18.05 | 2022 | |
| Olympus America INC. | $16.72 | 2023 | |
| Optinose US, INC. | $16.35 | 2024 | |
| Merck Sharp & Dohme LLC | $13.65 | 2021 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Jared Marks listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.